Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT
Trial Parameters
Brief Summary
This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering Shenque, Zhongguo, Guanyuan, and Qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.
Eligibility Criteria
Inclusion Criteria: 1. patients were fully aware of the study, participated voluntarily, and signed the informed consent form; 2. Age: 18-55 years old; 3. patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation; Exclusion Criteria: 1. refusal to participate in this clinical study; 2. broken or sensitized skin corresponding to the moxibustion site; 3. allogeneic hematopoietic stem cell transplantationpatients pretreated with the Reduced-intensity conditioning.